Nicox SA

ALCOX

FR0013018124

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:29 2024-05-03 am EDT			5-day change	1st Jan Change
0.38 ^EUR	-1.81%		+1.60%	-14.03%

Apr. 22	Nicox: cash position of 9.1 million euros at the end of March	CF
Feb. 28	Nicox, BlackRock Sign Deal for Debt Restructuring	MT

Nicox: HBM Healthcare Investments falls below 5% threshold

January 23, 2023 at 04:48 am EST

On January 18, HBM Healthcare Investments (Cayman) Ltd declared to the AMF that it had crossed below the thresholds of 5% of Nicox's capital and voting rights, and held 2,494,490 shares, or 4.98% of the ophthalmology company's capital and voting rights.

This crossing of thresholds resulted from the sale of Nicox shares on the market. The declarant stated that it held 400,000 warrants, exercisable until December 9, 2026 and giving the right to subscribe to 340,000 new shares at a unit price per share of 3.21 euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	HBM HEALTHCARE INVESTMENTS AG	190 CHF	+1.71%	+1.06%	1.45B
	NICOX SA	0.38 EUR	-1.81%	+1.60%	20.47M

Latest news about Nicox SA

Nicox: cash position of 9.1 million euros at the end of March	Apr. 22	CF
Nicox, BlackRock Sign Deal for Debt Restructuring	Feb. 28	MT
Nicox Names Chief Business Officer as New CEO	Feb. 28	MT
Nicox SA Announces CEO Changes	Feb. 28	CI
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan	Feb. 08	MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod	Jan. 31	MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA	Jan. 31	CI
Nicox: sales up 29% in 2023	Jan. 25	CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan	Dec. 14	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20	CI
Nicox: surrounded after market study	23-07-10	CF
Nicox's New Drug Application for Eye Drop Medicine Gets Priority Review Status in China	23-04-28	MT
Nicox Set for Euronext Growth Paris Transfer	23-04-26	MT
Nicox: new data on two compounds	23-04-26	CF
Nicox: Armistice Capital falls below 5% threshold	23-04-25	CF
Global markets live: ASML, Netflix, United Airlines, Morgan Stanley, Tesla...	23-04-19
Nicox: cash position shrinks, share price plummets	23-04-19	CF
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop	23-04-14	MT
Nicox: share price soars, progress on Zerviate in China	23-04-14	CF
Nicox SA Announces New Drug Application Submission for ZERVIATE in China	23-04-14	CI
Global markets live: UBS, Berkshire Hathaway, First Republic Bank, Goldman Sachs...	23-03-20
Nicox: reduced losses in 2022, but reduced cash flow	23-03-20	CF
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Nicox: HBM Healthcare Investments falls below 5% threshold	23-01-23	CF
Nicox: cash position reassuring, but sales still limited	23-01-18	CF

Chart Nicox SA

Duration

Period

More charts

Company Profile

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."

Sector

Pharmaceuticals

Calendar

2024-05-05 - Association for Research in Vision and Ophthalmology Meeting - Corinna Galli

More about the company

Income Statement Evolution

More financial data

Ratings for Nicox SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.38 EUR

Average target price

1 EUR

Spread / Average Target

+163.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
NICOX SA	-14.03%	20.47M
MERCK KGAA	+5.48%	71.19B
KYOWA KIRIN CO. LTD.	+12.55%	9.3B
SK BIOPHARMACEUTICALS CO., LTD.	-13.75%	5.01B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+4.51%	3.96B
INDIVIOR PLC	+21.10%	2.44B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B

Specialty & Advanced Pharmaceuticals

Nicox SA

Equities

ALCOX

FR0013018124

Pharmaceuticals

Nicox: HBM Healthcare Investments falls below 5% threshold

Stocks mentioned in the article

EPS Revisions